The results of a double-blind, placebo-controlled RCT of Silymarin (700 mg thrice daily for 48 weeks) in a Malaysian population with biopsy-proven NASH showed significantly decreased fibrosis and lowered serum ALT and AST levels compared to placebo. Here, GPT is linked to metabolic dysfunction-associated steatohepatitis.